Evidence map›Paper›PMID 38557897›Full record

ArticleActa neuropathologica2024

Landscape of brain myeloid cell transcriptome along the spatiotemporal progression of Alzheimer's disease reveals distinct sequential responses to Aβ and tau.

Astrid Wachter, Maya E Woodbury, Sylvia Lombardo, Aicha Abdourahman, Carolin Wuest, Emily McGlame, Timothy Pastika, Joseph Tamm, Nandini Romanul, Kiran Yanamandra and 19 more

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 3 institutions in 2 countries.

Astrid Wachter *AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.ORCID 0009-0001-3977-7832
Maya E Woodbury *AbbVie Inc., Cambridge, MA, USA. maya.woodbury@abbvie.com.ORCID 0000-0003-0613-0220
Sylvia LombardoAbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.ORCID 0000-0002-5207-6723
Aicha AbdourahmanAbbVie Inc., Cambridge, MA, USA.
Carolin WuestAbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.ORCID 0009-0008-2835-7841
Emily McGlameAbbVie Inc., Cambridge, MA, USA.
Timothy PastikaAbbVie Inc., Cambridge, MA, USA.
Joseph TammAbbVie Inc., Cambridge, MA, USA.
Nandini RomanulAbbVie Inc., Cambridge, MA, USA.
Kiran YanamandraAbbVie Inc., Cambridge, MA, USA.
Rachel BennettMassachusetts General Hospital, Boston, USA.
Gen LinAbbVie Pte Ltd, Singapore, Singapore.
Taekyung KwonAbbVie Inc., Cambridge, MA, USA.
Fan LiaoAbbVie Inc., Cambridge, MA, USA.
Corinna KleinAbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Yelena GrinbergAbbVie Inc., Cambridge, MA, USA.
Methasit Jaisa-AadMassachusetts General Hospital, Boston, USA.
Huan LiMassachusetts General Hospital, Boston, USA.
Matthew P FroschMassachusetts General Hospital, Boston, USA.
Markus P KummerAbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Sudeshna DasMassachusetts General Hospital, Boston, USA.
Tammy DellovadeAbbVie Inc., Cambridge, MA, USA.
Eric H KarranAbbVie Inc., Cambridge, MA, USA.
Xavier LangloisAbbVie Inc., Cambridge, MA, USA.
Janina S RiedAbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Alberto Serrano-PozoMassachusetts General Hospital, Boston, USA.
Robert V TalanianAbbVie Inc., Cambridge, MA, USA.
Knut BiberAbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Bradley T HymanMassachusetts General Hospital, Boston, USA.
AbbVie (United States) · USAbbVie (Germany) · DEHarvard University · US

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
Microvascular Stress as a Pathway to Neurodegeneration in Alzheimer'sR01AG071567 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Elise Bennett · 2022 to 2026
$2.1M
NIA NIH HHS P30 AG062421NIA NIH HHS R01 AG071567
6 · The paper itself

Abstract

Human microglia are critically involved in Alzheimer's disease (AD) progression, as shown by genetic and molecular studies. However, their role in tau pathology progression in human brain has not been well described. Here, we characterized 32 human donors along progression of AD pathology, both in time-from early to late pathology-and in space-from entorhinal cortex (EC), inferior temporal gyrus (ITG), prefrontal cortex (PFC) to visual cortex (V2 and V1)-with biochemistry, immunohistochemistry, and single nuclei-RNA-sequencing, profiling a total of 337,512 brain myeloid cells, including microglia. While the majority of microglia are similar across brain regions, we identified a specific subset unique to EC which may contribute to the early tau pathology present in this region. We calculated conversion of microglia subtypes to diseased states and compared conversion patterns to those from AD animal models. Targeting genes implicated in this conversion, or their upstream/downstream pathways, could halt gene programs initiated by early tau progression. We used expression patterns of early tau progression to identify genes whose expression is reversed along spreading of spatial tau pathology (EC > ITG > PFC > V2 > V1) and identified their potential involvement in microglia subtype conversion to a diseased state. This study provides a data resource that builds on our knowledge of myeloid cell contribution to AD by defining the heterogeneity of microglia and brain macrophages during both temporal and regional pathology aspects of AD progression at an unprecedented resolution.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsBrainHumansMicrogliaMyeloid Cellstau ProteinsTranscriptomeAmyloid beta-Peptidestau ProteinsAlzheimer’s diseaseMicrogliaMyeloid cellsSingle-nucleus RNA-sequencing

Identifiers

PMID38557897
PMCPMC10984903
OpenAlexW4393376307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.